期刊文献+

万拉法新治疗惊恐障碍疗效对比分析 被引量:1

The Comparison Study of Venlafaxine in Treatment of Panic Disorder.
下载PDF
导出
摘要 目的 对比分析万拉法新治疗惊恐障碍的治疗效果。方法 随机设观察组 ( 2 2例 )和对照组 ( 2 0例 ) ,并对两组进行HAMA、CGI、TESS和国内统一 4级疗效评定和比较。结果 两组间 HAMA治疗前和治疗后 4周末均 P>0 .0 5 ;治疗后 1周末和 2周末均 P<0 .0 0 1 ;治疗后 4周末与治疗前两组 HAMA均降分明显 ,均 P<0 .0 0 1。两组间 SI、GI比较 ,均为 P>0 .0 5 ;EI比较 ,P<0 .0 5 ;TESS比较 ,P<0 .0 0 1。两组疗效构成比的比较 ,P>0 .0 5。结论 万拉法新具有快速、有效和药物副反应相对轻微的特点 ,治疗依从性较好 ,不失为治疗惊恐障碍的首选药物。 Objective To clarify the Venlafaxine's treatment efficacy of panic disorder by comparison.Methods 42 Patients were divided into two groups,the Venlafaxine growp(n=22)and the contrast growp(n=20),HAMA,CGI and TESS were used to assess the efficacy and side effects.Results The effective rate of this two roups were similar.The serious degree of side effect was lower in Venlafaxine group than that of contrast group.Conclusion Venlafaxine is an effective conveniont and safe treatment in panic disorder.It had few side effects and can be a first drug choice.
出处 《健康心理学杂志》 2003年第5期358-359,共2页 Health Psychology Journal
关键词 万拉法新 惊恐障碍 药物治疗 对比分析 疗效 Venlafaxine Panic disorder HAMA TESS
  • 相关文献

参考文献2

二级参考文献3

  • 1李心天,医学心理学,1998年,402页
  • 2韩敬 (译),不再焦虑,1997年
  • 3许又新,神经症,1994年,75页

共引文献115

同被引文献14

  • 1Kessler RC , McGonagle KA , Zhao S, et al. Lifetime and 12-month prevalence of DSM-Ⅲ-R psychiatric disorders in the U-nited States: results from the national comorbidity Survey[J]. Arch Gen Psychiatry,1994, 51:8-19.
  • 2Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder[J]. J Clin Psychiatry,2001,62( suppl 11):22-27.
  • 3Ballenger JC . Overview of different pharmaeotherapies for attaining remission in generalized anxiety disorder [J]. J Clin Psychiatry, 2001,62(suppl 19) :11-19.
  • 4DeVane CL.Immediate-release versus controlled-release formulations : pharmacokinetics of newer antidepressants in relation to nausea [J]. J Clin Psychiatry, 2003,64 (suppl 18):14-19.
  • 5Rickels K ,Pollack MH ,Sheehan DV, et al: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder[J]. Am J Psychiatry, 2000,157:968-974.
  • 6Allgulander C,Hackett D , Salinas E .Venlafaxine extended re-lease(ER) in the treatment of generalised anxiety disorder [J]. Br J Psychiatry,2001,179:15-22.
  • 7Khan A, Khan S , Kolts R,et al. Suicide rate in clinical trials of SSRIS , other antidepressants , and placebo: analysis of FDA re-ports [J]. Am J Psychiatry, 2003,160:790-792.
  • 8Thase ME ,Entsuah AR , Rvdolph RL , et al. Remission rate during treatment with venlafaxine or SSRIs[J]. Br J Psychiatry, 2001, 178:234-241.
  • 9Upadhyaya HP, Brady KT, Sethuraman G. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit/hyperactivity disorder: A Pilot Study [J]. J Clin Psycho-pharmacology, 2001, 21:116-118.
  • 10Chial HJ,Camilleri M , Burton D , et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health[J]. Am J phys Gastrointest Liver Physiol, 2003, 284:130-137.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部